We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
German vaccine maker CureVac and the European Union (EU) are close to finalizing a supply deal for the company’s COVID-19 vaccine candidate that will stock the EU with hundreds of millions of doses. Read More
J&J’s Janssen subsidiary will explore nipocalimab’s usefulness for other autoimmune diseases, such as maternal-fetal disorders and neuro-inflammatory disorders. Read More
Johnson & Johnson (J&J) announced that it will acquire the autoimmune-focused biotech company Momenta Pharmaceuticals for $6.5 billion, expanding its holdings in the area of novel treatments for autoimmune diseases. Read More
Swiss pharma giant Roche is partnering with Regeneron Pharmaceuticals to ramp up production of the New York-based biotech’s COVID-19 antibody cocktail candidate, REGN-COV2. Read More
A federal court in Delaware has ruled that Novartis Pharmaceuticals’ patent for its best-selling multiple sclerosis drug Gilenya (fingolimod) is valid, and HEC Pharm has infringed on it. Read More
Sanofi has agreed to pay $3.7 billion for San Francisco-based Principia Biopharma, giving the French drugmaker full control of a potential multiple sclerosis drug. Read More